Tailstorm Health INC: Drug Recall

Recall #D-0051-2025 · 11/06/2024

Class II: Risk

Recall Details

Recall Number: D-0051-2025
Classification: Class II
Product Type: Drug
Recalling Firm: Tailstorm Health INC
Status: Terminated
Date Initiated: 11/06/2024
Location: Phoenix, AZ, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 27,560 Syringes

Reason for Recall

Lack of Sterility Assurance

Product Description

BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syringe, Rx Only, Repackaged by: Medivant Healthcare: 24416 N 19th Ave, Phoenix, AZ, NDC 81483-0041-1

Distribution Pattern

Nationwide Within U.S.

Other Recalls by Tailstorm Health INC

Class II: Risk 06/02/2025

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Class II: Risk 06/02/2025

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Class II: Risk 06/02/2025

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Class II: Risk 06/02/2025

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Class II: Risk 06/02/2025

Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

View all recalls by Tailstorm Health INC →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.